In lymphoma, JAK2 has been shown to up regulate the transcription of both PD-1 ligands (PD-L1, PD-L2) while increasing sensitivity to JAK2 inhibitors in a dose dependent manner25. This evidence concerns the gene PDCD1LG2 and lymphoma.